Engineering flavonoid-loaded nanocarriers for targeted anti-inflammatory therapy: a critical review of bioavailability barriers, mechanistic pathways, and translational challenges

Inflammation is a crucial immune response that aids in the healing of tissue damage and infection; nevertheless, its prolonged presence leads to the onset of serious conditions. Flavonoids, a varied group of polyphenolic chemicals found in fruits, vegetables, and tea, have attracted significant interest for their antioxidant, anti-inflammatory, and anti-carcinogenic characteristics. Despite preclinical and clinical studies endorsing their medicinal potential, the clinical application of flavonoids remains constrained. This review rigorously assesses the current research about the function of flavonoids in inflammatory disorders and explores recent developments in nanocarrier-based drug delivery methods. Significant focus is directed towards nanoparticulate platforms, designed to improve flavonoid stability, solubility, bioavailability, and targeted delivery. It demonstrates that flavonoid-loaded nanocarriers can alter pharmacokinetic behaviour by protecting flavonoids from first-pass hepatic metabolism, gastrointestinal degradation, and rapid systemic clearance: in the only reported human pharmacokinetic study, a lecithin-based quercetin phytosome produced an approximately 20-fold increase in Cmax and AUC relative to unformulated quercetin, while in preclinical models albumin nanoparticles raised plasma epigallocatechin-3-gallate concentrations by approximately 1.5-fold and extended its half-life to approximately 15.6 h relative to the free compound. Mechanistically, these carriers act chiefly through suppression of cyclooxygenase-2 (COX-2) activity and NF-κB-mediated production of pro-inflammatory cytokines such as TNF-α and IL-1β at the target site, alongside controlled and sustained drug release that enables site-specific targeting and reduces the systemic exposure associated with conventional flavonoid formulations. Advancements in nanocarrier technology offer a viable, though still largely preclinical, solution to the intrinsic problems of flavonoid-based therapies. Flavonoid-encapsulated nanocarriers, by addressing challenges of inadequate bioavailability and instability, hold clear potential for the treatment of inflammatory disorders, a potential that remains to be confirmed by disease-specific clinical trials.

Authors

Institutions

Publication Details

Journal
Health Nanotechnology
Published
2026-11-18
DOI
https://doi.org/10.1186/s44301-026-00044-6
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineering flavonoid-loaded nanocarriers for targeted anti-inflammatory therapy: a critical review of bioavailability barriers, mechanistic pathways, and translational challenges

SOUMYADIP GHOSH, Rana Mazumder, Shayeri Chatterjee, Avishek Sardar et al.
2 links
Health Nanotechnology
Nanoparticle-Based Drug Delivery
article

Engineering flavonoid-loaded nanocarriers for targeted anti-inflammatory therapy: a critical review of bioavailability barriers, mechanistic pathways, and translational challenges

SOUMYADIP GHOSH, Rana Mazumder, Shayeri Chatterjee, Avishek Sardar, Sk Sangram, Ritam Maity
article en

Abstract

Inflammation is a crucial immune response that aids in the healing of tissue damage and infection; nevertheless, its prolonged presence leads to the onset of serious conditions. Flavonoids, a varied group of polyphenolic chemicals found in fruits, vegetables, and tea, have attracted significant interest for their antioxidant, anti-inflammatory, and anti-carcinogenic characteristics. Despite preclinical and clinical studies endorsing their medicinal potential, the clinical application of flavonoids remains constrained. This review rigorously assesses the current research about the function of flavonoids in inflammatory disorders and explores recent developments in nanocarrier-based drug delivery methods. Significant focus is directed towards nanoparticulate platforms, designed to improve flavonoid stability, solubility, bioavailability, and targeted delivery. It demonstrates that flavonoid-loaded nanocarriers can alter pharmacokinetic behaviour by protecting flavonoids from first-pass hepatic metabolism, gastrointestinal degradation, and rapid systemic clearance: in the only reported human pharmacokinetic study, a lecithin-based quercetin phytosome produced an approximately 20-fold increase in Cmax and AUC relative to unformulated quercetin, while in preclinical models albumin nanoparticles raised plasma epigallocatechin-3-gallate concentrations by approximately 1.5-fold and extended its half-life to approximately 15.6 h relative to the free compound. Mechanistically, these carriers act chiefly through suppression of cyclooxygenase-2 (COX-2) activity and NF-κB-mediated production of pro-inflammatory cytokines such as TNF-α and IL-1β at the target site, alongside controlled and sustained drug release that enables site-specific targeting and reduces the systemic exposure associated with conventional flavonoid formulations. Advancements in nanocarrier technology offer a viable, though still largely preclinical, solution to the intrinsic problems of flavonoid-based therapies. Flavonoid-encapsulated nanocarriers, by addressing challenges of inadequate bioavailability and instability, hold clear potential for the treatment of inflammatory disorders, a potential that remains to be confirmed by disease-specific clinical trials.

Health NanotechnologyVol. 2(1)
Brainware University (IN), Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences (IN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon